All
Arden, Allergan team-up to market 'new' Prevage
October 4th 2005New York - In what is believed to be the first product collaboration between a cosmetics company and a drug, Elizabeth Arden Inc. and Allergan Inc., the pharmaceutical firm that markets and distributes Botox, have teamed up to market a reformulated version of Allergan's anti-aging product, Prevage.
Offer systemic therapy as first-line defense
September 1st 2005Buenos Aires — In selecting therapies for patients with psoriasis, dermatologists need to consider that psoriasis is a life-long, systemic disease that substantially affects a patient's quality of life, according to Alan Menter, M.D., chief of the division of dermatology at Baylor University Medical Center, Dallas.
Autologous cellular treatments show long-term results with contour defects
September 1st 2005Baltimore - Results of an exploratory phase 3 clinical trial demonstrate that injection of autologous living skin fibroblasts provides safe and effective correction of facial contour deformities that is sustained for at least 12 months, reports Robert A. Weiss, M.D.
Rejuvenating the face: New trends emerge
September 1st 2005National report - Even as new techniques, devices and pharmaceutical developments for facial contouring and wrinkle refinement proliferate for dermatologists and cosmetic surgeons, two trends are gaining momentum - one for the better and one for the worse, according to dermatologist David H. McDaniel, M.D., and his colleague, cosmetic surgeon Kyle S. Choe, M.D.
MAL-PDT clears Bowen's disease with excellent cosmesis
September 1st 2005National report — Photodynamic therapy using the topical photosensitizer methyl aminolevulinate 16 percent cream (Metvix, Galderma) is a non-invasive, well-tolerated, effective treatment for Bowen's disease, offering excellent cosmetic results, according to the findings of a multicenter, randomized, active- and placebo-controlled study, says Colin A. Morton, M.D., consultant dermatologist, Falkirk Royal Infirmary, Falkirk, Scotland.
M.D. travels to Vietnam, shares new techniques, resources
September 1st 2005Tri Nguyen, M.D. was 6 years old when he finally escaped from war-ravaged Vietnam in 1976. The exit route: his parents paid a French-Vietnamese woman leaving for France to adopt him. After a year in Paris, he was reunited with his family, who ultimately settled in the United States.
Building a private practice requires exacting standards, attention to detail
September 1st 2005Chicago — Running a successful private practice demands that dermatologists give their patients the best of everything, from pre- and postoperative care to drug samples and waiting-room d?cor, says Haines Ely, M.D., a Grass Valley, Calif.-based private practitioner and clinical professor of dermatology, University of California, Davis. Dr. Ely's office logs at least 50 patient visits daily.
Inform, entertain your patients while they wait
September 1st 2005Despite your best efforts in managing your schedule, patient waits and delays are inevitable in your dermatology practice. Because you are a service business, patient no-shows, delayed arrivals and your need to maximize revenue based on filling your time, create this predictable situation. You can simply expect patients to wait in an uncomfortable chair, staring at a portrait of you from 1986, with only a tattered magazine to read — or you can dazzle them.
Restraint helps avoid filler pitfalls
September 1st 2005Chicago — As physicians increasingly use injectable fillers and botulinum toxin as complementary treatments for facial rejuvenation, success depends on educating patients thoroughly and injecting products cautiously, says Seth L. Matarasso, M.D., clinical professor of dermatology at the University of California, San Francisco, School of Medicine.
Phase 3 studies demonstrate broad utility of lidocaine/tetracaine peel
September 1st 2005National report — Results achieved in a series of studies comprising an extensive phase 3 clinical research program support the conclusion that a self-occlusive lidocaine 7 percent/tetracaine 7 percent peel (LT peel) provides safe, rapid and effective anesthesia for a broad spectrum of cutaneous procedures.
Matrix metalloproteinases in tumor progression: Past, present, future teaches valuable lessons
September 1st 2005Anaheim, Calif. — Lessons can be learned from the failure of matrix metalloproteinases inhibitors (MMPIs) to make a difference in halting tumor progression in clinical trials, according to the president of the American Association for Cancer Research (AACR).